Oberland Capital

Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide-based medicines in Denmark. It has a portfolio of medicines in development stage focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes glepaglutide, a long acting GLP-2 analog, which is in Phase 3 clinical trials for the treatment of short bowel syndrome; and dasiglucagon, a stable glucagon analog for the treatment of severe hypoglycemia in diabetes and congenital hyperinsulinism, as well as for use in dual-hormone artificial pancreas for automated diabetes management. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; and Beta Bionics, Inc. to initiate home-use trial of the iLet bionic pancreas with dasiglucagon for autonomous bihormonal treatment of type 1 diabetes, as well as research agreement with Orbit Discovery Ltd. and Torrey Pines Institute for Molecular Studies. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. The company applies an asset-centric R&D model at scale to advance a portfolio of highly validated programs led by industry-leading teams. Each program is developed by a Centessa Subsidiary and supported by a centralized infrastructure and the Centessa management team.

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). Founded in 2008 and headquartered in Ann Arbor, Michigan, the company specializes in non-statin medications aimed at treating conditions such as atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia. Its primary product candidates include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which are designed to improve cholesterol management. Esperion also explores novel treatment approaches, including HDL Therapy, based on its understanding of high-density lipoprotein function. The company collaborates with Daiichi Sankyo Europe GmbH to enhance its research and development efforts.

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Primmune Therapeutics, Inc., a biotechnology company, develops small molecule orally administered toll-like receptor 7 (TLR7) agonist to stimulate innate immunity in cancer immunotherapy. It offers TLR7 agonist for systemic activation of innate immunity. The company’s TLR7 is an agonist for acute and chronic viral infection. The company was founded in 2017 and is based in San Diego, California.

NorthStar Medical Radioisotopes LLC (northstarnm.com) was founded in 2006 to address the needs of the nuclear medicine market in the United States. A wholly owned subsidiary of NorthStar Medical Technologies LLC, the company is committed to resolving industry-wide supply challenges that have caused shortages of vital medical isotopes, negatively impacting patient care and stalling clinical research. Its patented technologies include innovative non-uranium based molybdenum-99 production methods, a novel separation chemistry system and tools for the nuclear medicine market.

Impact Biomedicines, Inc. engages in the research, development, and commercialization of treatments for patients with myeloproliferative neoplasms and other cancers. Its product under late-stage development pipeline is fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded in 2016 and is headquartered in San Diego, California. As of February 28, 2018, Impact Biomedicines, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company specializing in the discovery, development, and commercialization of anti-infective therapies targeting bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which address various acute bacterial skin infections and gram-negative infections. Recognizing the urgent need for new antibiotics to combat drug-resistant infections, Melinta is advancing delafloxacin, currently in Phase 3 development for treating acute bacterial skin and skin structure infections. The company also focuses on developing innovative antibiotics aimed at overcoming resistant pathogens associated with serious hospital infections. Established in 2000, Melinta Therapeutics is headquartered in Morristown, New Jersey, and operates with support from strategic partners in the healthcare sector.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company specializing in the discovery, development, and commercialization of anti-infective therapies targeting bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which address various acute bacterial skin infections and gram-negative infections. Recognizing the urgent need for new antibiotics to combat drug-resistant infections, Melinta is advancing delafloxacin, currently in Phase 3 development for treating acute bacterial skin and skin structure infections. The company also focuses on developing innovative antibiotics aimed at overcoming resistant pathogens associated with serious hospital infections. Established in 2000, Melinta Therapeutics is headquartered in Morristown, New Jersey, and operates with support from strategic partners in the healthcare sector.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company specializing in the discovery, development, and commercialization of anti-infective therapies targeting bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which address various acute bacterial skin infections and gram-negative infections. Recognizing the urgent need for new antibiotics to combat drug-resistant infections, Melinta is advancing delafloxacin, currently in Phase 3 development for treating acute bacterial skin and skin structure infections. The company also focuses on developing innovative antibiotics aimed at overcoming resistant pathogens associated with serious hospital infections. Established in 2000, Melinta Therapeutics is headquartered in Morristown, New Jersey, and operates with support from strategic partners in the healthcare sector.